SAN DIEGO, May 12, 2011 /PRNewswire/ -- Naviscan, Inc., the leader in 3D Molecular Breast Imaging (MBI), has entered into a distribution agreement with Chindex Medical Limited to market and service Naviscan's high-resolution organ-specific PET scanner in the People's Republic of China, including Hong Kong and Macau. The agreement represents the introduction of PEM (Positron Emission Mammography), the scanner's breast application, as a new tool available to Chinese women in their fight against breast cancer.
Naviscan manufactures the only commercially-available PEM scanner and PEM-guided biopsy system. The scanner uses PET technology to produce tomographic images that allow physicians to visualize and biopsy breast tumors as small as 1.3 mm, the width of a grain of rice. In recently published data, PEM has been found to be significantly more precise at identifying benign and cancerous lesions, in what scientists call "specificity", therefore reducing the number of unnecessary biopsies. This finding is a welcomed outcome for women and physicians looking for ways to reduce the patient trauma and cost associated with unnecessary procedures.
Chindex Medical Limited is a specialized full-service distributor of high tech medical equipment in Greater China, including a strong presence in the minimally-invasive surgical and imaging sectors as the exclusive distributor for the Intuitive Surgical daVinci® Surgical Systems, and Siemens high-end ultrasound and Hologic mammography products. The Naviscan PET scanner is an ideal complement to Chindex Medical Limited's breast and surgery expertise and an ideal partner to continue its expansion in Asia.
About Naviscan, Inc.
Naviscan, founded in 1995, develops and markets compact, high-resolution PET scanners intended to provide organ-specific molecular imaging and guide radiological and surgical procedures. The Naviscan PET scanne